Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Photodynamic therapy combined with immunotherapy: Nov 15/23
View:
Comment by N0taP00p on Nov 16, 2023 9:51am
This to me, is the Holy Grail for Ruvidar.  Long research paper but glanced through it.. Even standalone,  the results have been great but when combined with an immunotherapy, should get amazing results.. The perception of lingering side effects needs to be overcome.   Even vaccines are mentioned in this paper.    But first, let's hope they get enough money to ...more  
Comment by N0taP00p on Nov 16, 2023 9:55am
Plus, this paper has SO many photosensitizers mentioned.  A lot of them still seem to be in animal studies mode.  Photofrin is mentioned. Couldn't find references to Ruvidar.  I'm sure it's in there somewhere.  
Comment by Jaro1977 on Nov 16, 2023 11:40am
We are mentioned; Ruvidar® (TLD-1433) ruthenium-based coordination compound 532 – 0.35–0.7 mg/cm2 Lung cancer, melanoma, non-muscle invasive bladder cancer [135] Reference S. Chamberlain, H.D. Cole, J. Roque 3rd, D. Bellnier, S.A.  ...more  
Comment by Rumpl3StiltSkin on Nov 16, 2023 12:37pm
Did they mention that Ruvidar is an immunotherapy? And that it has none of the PDC specific side effects? Or any adverse effects...? Still under the radar, for now.
Comment by Eoganacht on Nov 16, 2023 1:04pm
In case anyone missed it, Theralase applied for a new patent last month:  https://stockhouse.com/news/press-releases/2023/10/05/theralase-r-files-us-patent-for-enhanced-immunotherapy "...Theralase® announced that it has filed a US patent, titled "Enhanced Immunotherapeutic Method Comprising Combined Administration of Photodynamic / Radiotherapeutic Compounds and ...more  
Comment by Longholder99 on Nov 17, 2023 1:24pm
While we await these huge moves for a small company started by an Engineer with huge foresight.  We can and should consider and imagine the relief felt by these first patients living with healthy cancer free bladders that were headed to biohazard disposals.  Bless this company and its supporters. To those who badmouth and seek to drag it down.  Shame. 
Comment by Alamir1111 on Nov 17, 2023 1:47pm
Ok Long nice ..what would be the reason that tlt got no recognition from investment companies? Most small biotech got 15 to 25 investment co lined up .some have up to 100millions in cash...doing phase 1 snake oil?Hint Its not tsx exchange
Comment by Eoganacht on Nov 17, 2023 2:12pm
Good post Longholder99. In terms of patient welfare, it's gratifying to compare Adstiladrin's performance with that of Ruvidar PDT Of 103 CIS patients treated with Adstiladrin 24 of them still had a CR 15 months after their initial treatment. If Ruvidar PDT maintains only the current 33% CRR at 15 months this will mean 33 CR patients at 15 months. So for just the first 100 patients ...more  
Comment by DeathXray33 on Nov 18, 2023 4:49pm
Very well said... @>1.191 million now...
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250